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Wilms tumor, a common childhood tumor of the kidney, is thought to arise from undifferentiated renal mesenchyme.
Variable tumorhistology and the identificationof tumor subsetsdisplayingdifferent geneexpressionprofiles suggest that
tumors may arise at different stages of mesenchyme differentiation and that this ontogenic variability impacts tumor
pathology, biology, and clinical outcome. To test the tumorigenic potential of different cell types in the developing kidney,
we used kidney progenitor-specific Cre recombinase alleles to introduce Wt1 and Ctnnb1 mutations, two alterations
observed inWilms tumor, into embryonicmouse kidney,with andwithout biallelic Igf2 expression, another alteration that
is observed in a majority of tumors. Use of a Cre allele that targets nephron progenitors to introduce a Ctnnb1mutation
that stabilizes β-catenin resulted in the development of tumors with a predominant epithelial histology and a gene
expression profile in which genes characteristic of early renal mesenchyme were not expressed. Nephron progenitors
with Wt1 ablation and Igf2 biallelic expression were also tumorigenic but displayed a more triphasic histology and
expressed early metanephric mesenchyme genes. In contrast, the targeting of these genetic alterations to stromal
progenitors did not result in tumors. These data demonstrate that committed nephron progenitors can give rise toWilms
tumorsand that committed stromal progenitors are less tumorigenic, suggesting that humanWilms tumors that display a
predominantly stromal histology arise from mesenchyme before commitment to a stromal lineage.
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Wilms tumor is a kidney tumor diagnosed primarily in children under
the age of five. It is an embryonal tumor and typically exhibits a triphasic
histology comprised of cells at differing stages of differentiation that are
normally seen in the developing kidney: blastemal cells similar to early,
undifferentiated metanephric mesenchyme; epithelial cells arranged in
disorganized duct-like structures very similar to nephron ductal epithelial
cells; and stromal cells. During normal kidney development, each of
these cell types arises from intermediatemesenchyme, andWilms tumors
are generally thought to arise from undifferentiated intermediate and
metanephric mesenchyme. However, tumors are very heterogeneous
histologically, which has led to the suggestion that variable tumor
histology may be a result of mesenchymal cells being mutated andA
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example, some tumors display predominantly stromal or predominantly
epithelial elements, raising the question of whether this distinct histology
is the result of transformation of a cell already fated to become stromal or
nephron epithelium, respectively.
The kidney is derived fromOsr1 expressing intermediate mesoderm [1].
A very small population of cells expressing bothFoxd1 andSix2 is present at
the onset of metanephric mesenchyme outgrowth and can transiently
contribute to nephron epithelium fated cells [2,3]. Subsequently, twomajor
types of progenitor populations exist: nephron progenitors and stromal
progenitors [2,4–6]. Nephron progenitors give rise to the majority of the
cells in the nephron. The undifferentiated and self-renewing population of
uninduced nephron progenitors expresses Cited1 and Six2 [7]. Upon
stimulation of BMP7-Smad signaling, these cells lose expression of Cited1
but not Six2 and become sensitive to Wnt9/β-catenin signaling from the
ureteric bud, resulting in expression ofWnt4 and Lef1 and epithelialization
[8]. In comparison, stromal progenitors specifically express Foxd1 and give
rise to the interstitium, pericytes, and mesangial cells [2,6]. Thus, triphasic
Wilms tumors with blastemal (mesenchymal), epithelial, and stromal
elements have been thought to arise before the specification of nephron or
stromal progenitors. Similarly, stromal-predominant tumors have been
proposed to originate from a stromal progenitor.
Gene expression analysis of a large panel of Wilms tumors resulted in
the identification of five subsets of tumors which, in addition to their
differing expression profile, displayed differing genemutation frequencies,
histologic features, and clinical outcomes [9]. From this work, a model of
Wilms tumor ontogeny was proposed, but, to date, experimental data
regarding the cellular ontogeny of Wilms tumor have been lacking.
We previously successfully generated a genetic endogenous tumor
mouse model for Wilms tumor by somatically and mosaically
introducing into fetal kidney a combination of alterations observed in
human tumors: ablation of Wt1; a transcription factor essential for
kidney development; and biallelic expression of Igf2, a fetal mitogen.
This was accomplished by use of a ubiquitously expressing,
tamoxifen-inducible transgene encoding Cre-recombinase. Tumors
from these mice (U-Cre-Wt1-Igf2) recapitulated the classic triphasic
histology of human tumors [10]. This experimental system now
enables us to investigate whether mutations targeted to specific
cellular compartments of the developing kidney are tumorigenic and,
if so, whether the histology of tumors varies depending upon the
differentiation status of the targeted cell.
Using Cre alleles expressed specifically in FOXD1+, CITED1+, and
SIX2+ cells to target stromal and nephron progenitors, respectively, we
tested the tumorigenic effect of 1) Wt1 ablation and Igf2 biallelic
expression and 2) Wt1 ablation and Ctnnb1 (β-catenin) stabilizing
mutations, another combination of alterations observed in human
Wilms tumors [11], in these twomajor compartments of the developing
kidney. We found that, with these alterations, tumors developed from
nephron progenitors but not stromal progenitors. Moreover, introduc-
tion of a stabilizing Ctnnb1 mutation into nephron progenitors using
both the Cited1-Cre (Cited1Cre) and the Six2-Cre (Six2GCE) alleles
resulted in tumors irrespective of Wt1 ablation. Of note, these tumors
displayed an epithelial-predominant histology. In contrast, introduction
of Wt1-ablation and Igf2 biallelic expression (Wt1-Igf2) using the
Cited1Cre transgene was tumorigenic but not when the Six2GCE allele
was employed. These Cited1Cre-Wt1-Igf2 tumors displayed a triphasic
histology. Thus, both the differentiation status of the targeted cell and
the type of mutations introduced had a significant impact on
tumorigenesis.Materials and Methods
Mice
The Foxd1GCE (B6;129S4-Foxd1tm2(GFP/cre/ERT2)Amc/J), Six2GCE
(B6;129-Six2tm3(EGFP/cre/ERT2)Amc/J), Cited1Cre (Cited1-CreERTM-GFP),
R26 tdTomato (B6;129S6-Gt(ROSA)26Sor tm14(CAG-tdTomato)Hze/J),
Ctnnb1ex3(fl), Wt1- (B6.129S4-Wt1tm1Jae/J), Wt1fl, and H19− mouse
strains were used for these studies and have been described previously
[5,6,12–17]. In the Foxd1GCE and Six2GCE strains, a GFP-Cre cassette
is under the control of the endogeneous Foxd1 and Six2 promoters,
respectively, whereas the Cited1-CreERTM-GFP strain is a BAC
transgenic mouse line in which a GFP-Cre expression construct is
under the control of a 190-kb genomic fragment 5' of the Cited1 gene.
For all three Cre lines, Cre-recombinase function is inducible in a
dose-dependent manner by tamoxifen (TM), and embryos were treated
in utero with TM by intraperitoneal injection of the pregnant female to
induce Cre activity. Recombination of the Ctnnb1ex3(fl) allele results in
an in-frame deletion of exon 3 which stabilizes the resulting protein and
activates theWnt/β-catenin pathway [16]. Recombination of theWt1fl
allele results in ablation ofWt1 function [15]. TheH19− allele carries a
deletion of H19 and the imprinting control region (ICR1) that is
required for silencing of thematernal Igf2 locus.Maternal inheritance of
H19− (H19−m) results in biallelic expression of Igf2 [17].
Mice were maintained on a C57BL/6 J × 129/SvEv mixed genetic
background, housed in a pathogen-free environment, and handled
according to the guidelines of The University of Texas MD Anderson
Cancer Center Institutional and Animal Care and Use Committee.
Overall, similar numbers of male and female mice were used.
Genotyping
Genotyping of mice (tail and normal tissue DNA) and tumors (tumor
DNA) was carried out using previously described conditions [10].
Validation of Progenitor Cell-Type Specific Expression of
Cre Alleles
To confirm the progenitor specificity of the different Cre alleles and
to estimate the proportion of kidney cells resulting from progenitor-
specific targeting, Foxd1GCE/+, Six2GCE/+, or Cited1Cre/+ mice were
crossed with tdTomato reporter mice expressing the loxP-Stop-loxP
tdTomato transgene (R26tdTomato). Cre+; R26tdTomato/+ embryos were
treated with TM (1 or 3 mg/40 g body weight [BW]) at E11.5, E14.5,
or E17.5. Embryonic kidneys were harvested at E19.5 and assessed by
immunofluorescence (IF) histology. To estimate the frequency of
Cre-mediated recombination, kidneys were also harvested at E14.5 and
E19.5 and dissociated into single-cell suspensions which were sorted by
fluorescence-activated cell sorting analysis (FACS) as described below.
Generation of Tumor-Watch Cohorts
To generate tumor-watch cohorts, Cre+; Wt1+/− males were bred
with Wt1 fl/fl; Ctnnb1ex3(fl)/ex3(fl) or Wt1fl/fl; H19−/− females to
generate embryos with the following genotypes: 1) Foxd1GCE;
Wt1−/fl or Wt1+/fl; Ctnnb1+/ex3(fl) (F-Wt1-β-catS), 2) Foxd1GCE;
Wt1−/fl; H19+/−m (F-Wt1-Igf2), 3) Six2GCE; Wt1−/fl or Wt1+/fl;
Ctnnb1+/ex3(fl) (S-Wt1-β-catS), 4) Six2GCE; Wt1−/fl; H19+/−m
(S-Wt1-Igf2), 5) CitedCre; Wt1−/fl; Ctnnb1+/ex3(fl) (C-Wt1-β-catS),
and 6) CitedCre; Wt1−/fl; H19+/−m (C-Wt1-Igf2). Embryos were
treated by intraperitoneal injection of pregnant dames with TM (0.5,
1 or 3 mg/40 g BW) to induce Cre activity in specific fetal kidney
progenitors. For Foxd1GCE, TM was administered at E11.5. For
Six2GCE, TM was administered at E11.5 or E14.5. In addition to its
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in fetal liver progenitors at E14.5, and β-catenin activation by
Cited1Cre at E14.5 in the fetal liver led to the development of
hepatocellular carcinoma at an early age inN90%ofmice [18]. Because of
this competing phenotype, C-Wt1-β-catS embryos were treated at
E17.5, at which point Cited1Cre expression was undetectable in fetal
liver [18] but still robust in fetal kidney.Wt1 ablation with Cited1Cre in
the context of Igf2 biallelic expression following TM injection at E14.5
did not result in a detectable liver phenotype, and this time point was
used to generate the C-Wt1-Igf2 cohort. Mutant mice and littermate
controls were monitored for tumor development.
Histology and Immunohistochemistry
Tumor and kidney tissue specimens for hematoxylin and eosin
(H&E) and immunohistochemistry (IHC) analyses were fixed in 4%
paraformaldehyde, embedded in paraffin, and cut into 5-μm sections.
Samples for IF staining were processed in ornithine carbamoyltrans-
ferase compound and cut into 12-μm frozen sections. H&E, IHC,
and IF analyses of proteins were performed as described previously
[10]. Antibodies used were: WT1 (sc-192, Santa Cruz Biotechnology),
Ki67 (ab15580, Abcam), pHH3 (06-570, Upstate Biotechnology),
β-catenin (610154, BD Biosciences), Dlk1 (sc-8624, Santa Cruz
Biotechnology), Cited1 (9219, Fisher Scientific), Six2 (11562-1-AP,
Proteintech), Pax2 (PRB-276P, Covance), NCAM (C9672, Sigma),
E-cadherin (3195, Cell Signaling Technology), K-cadherin (ab79005,
Abcam), Vimentin (V2258, Sigma), Collagen IV (AB756P, Chemicon),
Cyclin D1 (sc-753, Santa Cruz Biotechnology), and C-myc (9E10, Santa
Cruz Biotechnology).
Fluorescence-Activated Cell Sorting Analysis
Single-cell suspensions from fetal kidneys harvested at E15.5 or
E19.5 from Foxd1GCE/+; R26tdTomato/+ embryos, Six2GCE/+; R26-
tdTomato/+ embryos, and Cited1Cre/+; R26tdTomato/+ embryos were
prepared as previously described [5]. Cells expressing tdTomato as a
result of Cre-mediated recombination of the conditionally expressed
tdTomato reporter were isolated with the BD FACS Aria high-speed
digital cell sorter (BD Biosciences). Cell suspensions from littermate
kidneys without a Cre allele served as negative controls.
Gene Expression Analysis
Tumor or kidney tissue was flash-frozen in liquid nitrogen. RNA
was extracted from specimens or cell pellets using the RNA-
queous-4PCR kit (Ambion) and converted to cDNA using reverse
transcription reagents (Applied Biosystems). Real-time polymerase
chain reaction (PCR) was performed using SYBR Green reagent with
a 7900HT sequence detection system (Applied Biosystems) using
transcript-specific primers (Supplementary Table 2).
Statistical Analysis
The Student t test or analysis of variance was used to analyze real-time
PCR results. Results were presented as mean values with standard
deviation. P values less than .05 were considered statistically significant.
Results
Validation of Progenitor Cell-Type Specific
Expression of Cre Alleles
Lineage tracing of cells derived from targeted progenitors
confirmed the specificity of the Cre alleles used (Figure 1A). As
expected, use of the Six2GCE and Cited1Cre alleles resulted intdTomato expression in nephron progenitors and their daughter cells,
e.g., comma-shaped bodies, S-shaped bodies, proximal tubules, distal
tubules, and glomeruli. Also as expected, as the time between TM
injection and harvesting the kidney increased, tdTomato expression
shifted more medially as labeled progenitors differentiated and kidney
development continued at the periphery. Use of the stromal
progenitor-specific Cre (Foxd1GCE) resulted in labeled stromal progenitors
and their descendent cells. FACS analysis of kidney cell suspensions for
tdTomato+ cells at E15.5 and E19.5 was also carried out. A representative
FACS sorting plot is shown inFigure 1B. tdTomato+ cells represented 30%
to 33% of total kidney cells following Six2GCE-mediated recombination
and 5% to 7% following recombination with either the Cited1Cre or
Foxd1GCE alleles (Figure 1C and Table 1).
Targeting of Nephron, But Not Stromal, Progenitors Results in
Wilms Tumor Development
As shown in Table 2, Wt1−/fl; Ctnnb1+/ex3(fl) cohorts carrying
either the Six2GCE or CitedCre Cre-recombinase-expressing allele
developed tumors. The age of onset observed in these two genotypes
was similar (Figure 2), and tumor frequency was also similar, despite
the increased frequency of recombined cells observed using the
Six2GCE allele (Table 1). In contrast, Wt1 ablation and biallelic
expression of Igf2 (Wt1−/fl; H19+/−m genotype) resulted in tumors
only when nephron progenitors were targeted using the CitedCre allele
(9/18 mice) but not the Six2GCE allele (0/28 mice). When CitedCre
was used to target nephron progenitors, tumors arising followingWt1
ablation in the context of Igf2 biallelic expression (C-Wt1-Igf2 mice)
developed at a significantly later age (P = .0058) than when Wt1 was
ablated in the context of β-catenin stabilization (C-Wt1-β-catS mice).
No tumors were observed in animals in which Wt1 ablation in the
context of either β-catenin stabilization or Igf2 biallelic expression was
targeted to stromal progenitors (F-Wt1-β-catS and F-Wt1-Igf2
cohorts) (Figure 2A, Table 2).
β-Catenin Stabilization Is Sufficient for Tumor Development
in Nephron-Progenitor Targeted Cells
Genotyping of tumors confirmed that, as expected, all tumors from
Six2GCE; Wt1−/fl; Ctnnb1+/ex3(fl) animals and Cited1Cre; Wt1−/fl;
Ctnnb1+/ex3(fl) animals carried the recombined Ctnnb1ex3(fl) (Ctnnb1-
) allele. Unexpectedly, many tumors (11/14) retained the unrecombined
Wt1fl allele (Figure 2B), indicating thatWt1 ablation was not required for
transformation of the nephron progenitors. Six2GCE; Wt1−/fl; Ctnnb1+/ex3(fl)
mice, Six2GCE; Wt1+/fl; Ctnnb1+/ex3(fl) mice, Cited1Cre; Wt1−/fl; Ctnnb1+/
ex3(fl)mice, andCited1Cre;Wt1+/fl; Ctnnb1+/ex3(fl)mice developed tumors at
a similar rate and at similar ages regardless of differential gene dosages of
Wt1 (Figure 2A). To confirm that β-catenin stabilization alone was
sufficient for tumorigenesis, we generated a small cohort of Six2GCE;
Ctnnb1+/ex3(fl) mice. By 35 weeks of age, 2 of 5 animals developed
tumors, similar to the observations in the Six2GCE; Wt1−/fl; Ctnnb1+/
ex3(fl) and Six2GCE; Wt+/fl; Ctnnb1+/ex3(fl) mice (data not shown).
Of note,Wt1 ablation was observed in all tumors from theCited1Cre;
Wt1−/fl; H19+/−m mice (Figure 2C), and none of the six Cited1Cre;
Wt1+/fl; H19+/−m littermate control mice developed tumors.
Tumor Morphology and Histology
Tumors from the S-Wt1-β-catS and C-Wt1-β-catS cohorts were
often associated with benign blood-filled cysts, although this occurred
less frequently in C-Wt1-β-catS cohorts. Such cysts were not observed
in tumor-bearing C-Wt1-Igf2 mice. In all three genotypic cohorts,
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Figure 1. Efficiency of Cre recombination in progenitor-specific Cre lines using R26tdTomato reporter mice. (A) Kidney sections from
Six2GCE/+; R26tdTomato/+ (a and b), Cited1Cre; R26tdTomato/+ (c and d), and FoxD1GCE/+; R26tdTomato/+ (e) were treated with TM at indicated
timepoints and analyzed for tdTomato reporter expression at E19.5. DAPIwasused to counterstain nuclei. Scale bar: 200μm. (B) Representative
dot-plot of tdTomato+ cells from single cell suspension of Cited1Cre; R26tdTomato/+ kidney at E19.5 after 3 mg/40 g BW TM treatment at E14.5.
(C) FACS analysis showing percentage of targeted tdTomato+ cells from Six2GCE, Cited1Cre, and Foxd1GCE, respectively. Bar labels indicate the
embryonic age at the time of TM injection, the embryonic age at time of kidney collection, and the dose of TM used.
Table 2. Summary of Mouse Mutant Cohorts and TM Injection Conditions
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kidney (Figure 3A).
Tumors from the S-Wt1-β-catS and C-Wt1-β-catS cohorts
displayed an epithelial histology, composed mainly of primitive
epithelial cells which formed rosettes (Figure 3B, a and b) and more
differentiated epithelial cells which formed tubular structures
(Figure 3B, e and f). Stromal elements were observed in areas of
some tumors but were generally a very minor feature of the tumors.
Blastemal elements were even less frequently observed compared with
C-Wt1-Igf2 tumors. A similar tumor histology was observed irrespective
of whether Wt1 was ablated.
Targeting Nephron Progenitors with Different Mutations
Results in Histologically Different Wilms Tumors
In contrast to the tumors from S-Wt1-β-catS and C-Wt1-β-catS
cohorts, tumors from the C-Wt1-Igf2 cohort displayed a triphasicTable 1. Efficiency of Progenitor-Specific Cre-Mediated Recombination by FACS Analysis of
tdTomato+ Cells with Indicated TM Injection Conditions
Cre Time point of TM injection TM dosage FACS tdTomato+ cells %
Six2GCE E11.5 1 mg E15.5 33.7
E19.5 30.2
E14.5 3 mg E19.5 30.0
Cited1Cre E14.5 1 mg E19.5 6.8
E17.5 1 mg E19.5 5.1
Foxd1GCE E11.5 3 mg E15.5 7.1
E19.5 7.0histology comprised of undifferentiated blastemal, and differentiating
epithelial and stromal cells, similar to that observed in the original
WT mouse model in which somatic, mosaic Wt1 ablation in the
context of Igf2 biallelic expression was effected using a TM-inducible
Cre that is expressed ubiquitously (Figure 3B, c and d) [10].
Expression of β-Catenin and Wnt-β-Catenin Pathway Targets
in Tumors
To confirm the stabilization of β-catenin in tumors carrying the
Ctnnb1ex3Δ allele and to assess the impact of this stabilization on the
expression of canonical Wnt/β-catenin target genes, we performed
IHC for β-catenin and quantified the expression of downstream
targets in tumors. As shown in representative tumors in Figure 4A,
robust nuclear β-catenin staining was present in tumors from bothDesignation Genotype Tamoxifen
(mg/40 g BW)
Tumor mice/
mutant mice
S-Wt1-Igf2 Six2GCE, Wt1−/fl, H19+/−m 1 at E11.5 0/21
2 at E14.5 0/7
S-Wt1-β-catS Six2GCE, Wt1−/fl, β-cate3+/fl 3 at E14.5 8/11 (73%)
Six2GCE, Wt1+/fl, β-cate3+/fl 3 at E14.5 6/12 (50%)
S-β-catS Six2GCE, β-cate3+/fl 3 at E14.5 2/5 (40%)
C-Wt1-Igf2 Cited1Cre, Wt1−/fl, H19+/−m 1 at E14.5 9/18 (50%)
C-Wt1-β-catS Cited1Cre, Wt1−/fl, β-cate3+/fl 0.5 at E17.5 9/20 (45%)
Cited1Cre, Wt1+/fl, β-cate3+/fl 0.5 at E17.5 3/7 (43%)
F-Wt1-Igf2 Foxd1GCE, Wt1−/fl, H19+/−m 3 at E11.5 0/9
F-Wt1-β-catS Foxd1GCE, Wt1−/fl, β-cate3+/fl 3 at E11.5 0/17
Foxd1GCE, Wt1+/fl, β-cate3+/fl 3 at E11.5 0/11
AB S-Wt1-/fl-β-catS
Ctnnb1+ or ex3(fl)
Ctnnb1ex3Δ
T1 T1 T1T2 T2 T2
T1 T2 T1 T2
C-Wt1-/fl-Igf2 Normal
KidneyT1 T1T2 T2
Wt1fl
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TailS-Wt1+/fl-β-catS C-Wt1-/fl-β-catS
S-Wt1-/fl-β-catS S-Wt1+/fl-β-catS C-Wt1-/fl-β-catS
n=21
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Figure 2. Development of WT from nephron progenitors. (A) Kaplan-Meier tumor-free survival analysis showing incidence of WT
in Six2GCE, Cited1Cre, and Foxd1GCE mutant mice withWt1 ablation/haploinsufficiency and β-catenin stabilization (S/C/F-Wt1−/fl-β-catS and
S/C/F-Wt1+/fl-β-catS) and Wt1 ablation and Igf2 upregulation (S/C/F-Wt1−/fl-Igf2) in comparison to control mice. (B) PCR analysis of DNA
frommutant mice showing Ctnnb1wild-type or exon3 floxed allele and exon3 deleted allele (Ctnnb1+ or Ctnnb1ex3(fl) and Ctnnb1ex3Δ) and
Wt1 floxed or null alleles (Wt1fl or Wt1Δ).
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Figure 3. Histological analysis of WTs from Six2GCE and Cited1Cre mice. (A) Gross appearance of tumors from Six2GCE mice (a) and
Cited1Cre mice (b and c) of the indicated genotypes. (B) H&E staining of kidney tumor sections of S-Wt1-β-catS, C-Wt1-β-catS, and
C-Wt1-Igf2 mice. Scale bar: 100 μm.
Neoplasia Vol. 18, No. 2, 2016 Nephron Progenitor Cells Give Rise to Wilms Tumors Huang et al. 75
76 Nephron Progenitor Cells Give Rise to Wilms Tumors Huang et al. Neoplasia Vol. 18, No. 2, 2016S-Wt1-β-catS and C-Wt1-β-catS cohorts. The presence or absence ofWt1
ablation did not affect this robust staining (data not shown). However,
β-catenin in theC-Wt1-Igf2 tumors was primarily cytoplasmic (Figure 4A).
Tumors in which β-catenin was stabilized generally displayed increased
expression of Axin2, Wif1, and Dkk2, genes previously reported to
be upregulated upon Wnt/β-catenin activation, although there was
considerable tumor variability in the expression of Axin2 and Dkk2.
Despite this variability, there were significant differences in Axin2
expression between Cited1Cre-targeted tumors with β-catenin stabilization
versus Cited1Cre-targeted tumors with Wt1 ablation and Igf2 biallelic
expression. Upregulation of Wif1 was less variable and was dramatically
increased in β-catenin stabilized tumors.Within the sameCited1Cre-targeted
progenitor population, increased Wif1 expression was observed in the
C-Wt1-β-catS tumors but not theC-Wt1-Igf2 tumors, consistent withWif1
being a target of theWnt/β-catenin pathway. Unexpectedly, contrasting data
were obtained for CyclinD1 and C-myc, two other Wnt/β-catenin targets
whose expression was significantly higher in tumors not carrying the
stabilizing Ctnnb1mutation (Figure 4B).
Tumors from S-Wt1-β-catS and C-Wt1-β-catS Mice Have
Different Expression Patterns of Differentiation Markers than
Tumors from C-Wt1-Igf2 Mice
Differential expression of genes variably expressed in different renal
lineages and at different stages of differentiation was noted between
subsets of humanWilms tumors, and these data were used to construct
a model of the cellular ontogeny of Wilms tumors [9]. Having targetedA
B
Figure 4. Activity of Wnt/β-catenin signaling in mouseWTs. (A) IHC st
tumors from S-Wt1-β-catS, C-Wt1-β-catS, and C-Wt1-Igf2 mutants. S
effectors Axin2, CyclinD1, and C-myc and signaling inhibitors Wif1
C-Wt1-β-catS, and C-Wt1-Igf2 mutants. The x-axis labels indicate
progenitor-specific Cre alleles (Six2GCE or Cited1Cre) or Ubiquitous-Cre
(Wt1−/ ) or Igf2 upregulation (H19+/−m) in mouse tumors.different sets of mutations to different cellular compartments of the
developing kidney, we were in a position to test whether resulting
tumors displayed differential expression of these developmentally
regulated genes.
Tumors arising following the targeting β-catenin stabilization
to committed epithelial progenitors—by either Six2GCE or
Cited1Cre—displayed low expression of genes primarily expressed in
the intermediate renal mesenchyme and/or later metanephric mesen-
chyme (Eya1,Osr1, Pax2, andHoxa11) (Figure 5). However, targeting
Wt1 ablation in the context of Igf2 biallelic expression to nephron
progenitors using the same Cited1Cre transgene resulted in tumors that
robustly expressed these early stage genes. This expression of early
mesenchymal genes was similar to that observed in tumors when the
same mutations were introduced via the ubiquitously expressed
Cre-ERTM allele in the original WT mouse model (Figure 5) [10,19].
Robust expression ofWnt4 and Jag1, markers of induced mesenchyme,
and CyclinD1, whose expression is transiently upregulated following
induction, was observed only in tumors with Wt1 ablation and Igf2
biallelic expression. Expression of muscle differentiation genes was often
variable between tumors within a cohort and also between cohorts
(Supplementary Figure 1). Whereas a statistically significant increase in
expression was observed for some genes, e.g., Pax3 inCited1-β-catS and
Six1-Wt1-β-catS tumors and Ttn in Cited1-Wt1-Igf2 tumors, this was
not consistent across the three muscle differentiation genes we assessed.
Assessment of protein expression by IHC staining confirmed that
S-Wt1-β-catS and C-Wt1-β-catS tumors did not express PAX2 oraining of β-catenin and C-myc for sections from control kidneys and
cale bar: 100 μm. (B) qPCR analysis of Wnt/β-catenin canonical
and Dkk2 in littermate kidneys and tumors from S-Wt1-β-catS,
wild-type (Wt1+/fl) in littermate kidneys and the presence of
(U) and the presence of genetic alterations of β-catS,Wt1 ablation
Figure 5. Expression of differentiation markers in WTs of Six2GCE and Cited1Cre mice. qPCR analysis of early metanephric mesenchyme
markers (Eya1, Osr1, Pax2, Hoxa11, and Hmga2) and renal vesicle markers (Wnt4 and Jag1) in littermate kidneys and tumors from
S-Wt1-β-catS, C-Wt1-β-catS, and C-Wt1-Igf2mutants. The x-axis labels indicate wild-type (Wt1+/fl) in littermate kidneys and the presence of
progenitor-specific Cre alleles (Six2GCE or Cited1Cre) or Ubiquitous-Cre (U) and the presence of genetic alterations of β-catS,Wt1 ablation
(Wt1−/ ) or Igf2 upregulation (H19+/−m) in mouse tumors.
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All three tumor types expressed CITED1, a marker of nephron
progenitors and, in epithelial elements, expressed E-cadherin, a
marker of terminally differentiated epithelium.
In summary, both gene and protein expression data revealed that
C-Wt1-Igf2 tumors expressed markers of early mesenchyme and
also postinduction genes, whereas S-Wt1-β-catS and C-Wt1-β-catS
tumors expressed markers of committed nephron progenitors and
epithelial differentiation.
Discussion
Classically, three cell types—blastemal, stromal, and epithelial—are
observed in Wilms tumors, and such triphasic tumors have been
thought to arise from early undifferentiated metanephric mesen-
chyme. However, the observation of tumors comprised predomi-
nantly of stromal or epithelial elements has led to the suggestion that
these tumors arise from fetal kidney cells committed to a stromal or
epithelial lineage. The main goals of the current study were to
determine if tumors could arise from such committed progenitors
and, if they did, whether the resultant tumors displayed a
characteristic histology and whether the type of genetic alterations
introduced into renal progenitors affected their tumorigenicity and/or
the histology of the resulting tumors.
Using a Cre-LoxP approach, we earlier demonstrated that random
somatic and mosaic Wt1 ablation in the context of Igf2 biallelic
expression, a combination of alterations observed in human Wilms
tumors, resulted in mouse tumors with a classic triphasic histology
[10]. We have now introduced that same set of mutations and also the
combination of Wt1 ablation and β-catenin stabilization, another
combination that is also observed in human WTs [11], into specificcellular compartments of the developing kidney using TM-inducible
Cre-expressing alleles that target kidney stromal progenitors or
nephron progenitors.
Confirmation of Appropriate Targeting of Kidney Progenitors
Our lineage tracing experiments confirmed the expected progen-
itor-specific expression of each of the Cre alleles employed in the
study: kidney stroma was derived from FoxD1GCE-tdTomato–tagged
cells, whereas Six2GCE-tagged and Cited1Cre-tagged cells were present
in the cap mesenchyme population at early time points following Cre
induction and at later time point in the comma-shaped and S-shaped
bodies of developing nephrons and also the tubules and glomeruli of
mature nephrons. Interestingly, the tdTomato+ cells present 5 days
following targeting by Six2GCE existed in more mature structures
than those present 5 days following targeting by Cited1Cre at the same
time point. Six2GCE-tdTomato+ cells also represented a larger
percentage of the total kidney cell population than Cited1-
Cre-tdTomato+ cells. Both SIX2 and CITED1 have been identified
as markers for committed nephron progenitors, which are ultimately
induced to undergo a mesenchyme-epithelial transition in response to
WNT9b from the ureteric bud [4,5]. However, recent work suggests
a more nuanced compartmentalization in which CITED1+ SIX2+
cells, which are nonresponsive to WNT9b induction, lose expression
of CITED1, resulting in SIX2+-only cells that do respond to
WNT9b-induced epithelialization [8]. Thus, CITED1+ SIX2+ cells
are proposed to represent the self-renewing nephron progenitor
compartment, whereas SIX2+ cells represent cells that can then
respond to WNT9b and β-catenin.
Our observation of more differentiated tdTomato+ cells following
targeting by Six2GCE is consistent with this model. Unlike the Cited1-
78 Nephron Progenitor Cells Give Rise to Wilms Tumors Huang et al. Neoplasia Vol. 18, No. 2, 2016targeted population, the Six2-targeted population would include cells on
the cusp of epithelial differentiation, resulting in Six2GCE-tdTomato+ cells
being observed at later stages of nephron development. This model could
also account for the greater proportion of Six2GCE-tdTomato+ cells than
Cited1Cre-tdTomato+ cells 5 days following TM-induced tdTomato
expression.
Tumors Develop Following Mutational Targeting of
Nephron Progenitors
Tumors were observed in both the S-Wt1-β-cat S and
C-Wt1-β-catS cohorts, demonstrating that Wilms tumors can arise
from committed nephron progenitors. Interestingly, a similar
frequency of tumor development and age of onset was observed in
mice following targeting of Wt1 ablation and β-catenin stabilization
with Cited1Cre or Six2GCE, despite the tdTomato-lineage tracing data
that indicated a five-fold increase in the percentage of cells following
Six2GCE- versus Cited1Cre-induced labeling. This observation could
be due to the rapid differentiation of Six2GCE-tdTomato+ cells to a
more differentiated cell type that was refractory to transformation by
the introduced mutations. A previous study reported development of
mouse primitive epithelial tumors with features of Wilms tumors by
using Cited1Cre to activate β-catenin with or without K-ras activation
postnatally [20]. In this study, a proximal tubule specific γGT-Cre
was also applied to activate β-catenin, and K-ras and mutant mice
developed metastases to the lungs in addition to the primitive
epithelial tumors [20]. These tumors appeared histologically very
similar to our S-Wt1-β-catS and C-Wt1-β-catS epithelial Wilms
tumors. In our study, Six2GCE or Cited1Cre was activated at an early
stage of kidney development, and nephron progenitors were targeted,
which was different from the approach of targeting cells postnatally in
their models. Moreover, in S-Wt1-β-catS and C-Wt1-β-catS mutants,
a strong association of cystic kidney phenotype was observed with
tumor development. Combined, these results suggest that, with
β-catenin activation, both nephron progenitors and proximal tubules
can give rise to renal epithelial tumors in mice.
Another striking and statistically significant difference between
Six2GCE- versus Cited1Cre-targeted cohorts was the tumorigenic effect
of the combination of Wt1 ablation and Igf2 biallelic expression. No
tumors arose in S-Wt1-Igf2 animals (in which both the CITED1+
SIX2+ and the SIX2+-only progenitor populations were targeted),
whereas 50% (9/18) of C-Wt1-Igf2 animals (in which only the
CITED1+ SIX2+ population is expected to be targeted) developed
tumors (Figure 2A, Table 2). These differences between the Six2CGE
and Cited1Cre cohorts may be due to differences in the cells targeted by
these two Cre alleles. In the metanephric mesenchyme surrounding the
ureteric bud, two compartments, one CITED1+ SIX2+ and one SIX2+
only, have been delineated [7,8]. Whereas the robust expression of the
Cre alleles in the metanephric mesenchyme surrounding the ureteric
bud has been demonstrated by immunofluorescence analysis [5], less
robust expression of these alleles elsewhere in the developing
mesenchyme is possible and perhaps to be expected given that
endogenous Six2 and Cited1 expression is observed at low levels at
earlier stages of kidney development [12,21,22]. Of note, in contrast to
the frequent co-occurrence of Ctnnb1 and WT1 mutations in human
Wilms tumors [11], Sanger sequencing revealed thatC-Wt1-Igf2mouse
tumors did not spontaneously acquire Ctnnb1 mutations (Huff,
unpublished).
Another possible explanation for the difference in the tumorigenic
effect of Wt1 ablation and Igf2 biallelic expression in the Six2CGEversus the Cited1Cre cohort could be related to the experimental
approaches used for this study which result in additional differences in
Six2GCE- and Cited1Cre-targeted cells. Animals carrying the Six2GCE
allele in which the Cre-GFP cassette is knocked into the Six2 locus
are effectively Six2+/−. Six2 encodes a transcription factor that plays
an important role in nephron progenitor self-renewal [23,5,24].
Whereas Six2+/− mice have no discernable kidney phenotype [25],
suggesting that nephron progenitor self-renewal is unaffected by Six2
haploinsufficiency, such haploinsufficiency could plausibly impact
the ability of Ctnnb1-mutant cells to become tumors. SIX2 and
β-catenin are reported to act in both an opposing and a cooperative
manner to regulate different subsets of genes during epithelialization
of induced nephron progenitors [24]. If Six2 haploinsufficiency is a
factor in the differential tumor development in our experimental
cohorts, the data would suggest that, in the context of β-catenin
stabilization, Six2 haploinsufficiency helps to promote tumorigenesis
of nephron progenitors or that Six2 haploinsufficiency is incompat-
ible with tumor development in the context of Wt1 ablation and
biallelic Igf2 expression. Heterozygous SIX2 missense mutations are
observed in human Wilms tumors and are often coincident with
mutations in miRNA processing genes [26,27]. Neither WT1 nor
CTNNB1 mutations were observed in SIX2-mutant tumors. These
data are consistent with the model that, in our mice, Six2
haploinsufficiency was not a factor in the differential tumor
development we observed between the Six2-Cre and Cited1-Cre
cohorts upon the introduction of Wt1 and Ctnnb1 mutations,
although further studies will be required to test this experimentally.
Of note, in human tumors, IGF2 loss of heterozygosity or loss of
imprinting (which results in biallelic expression) is very common and
is observed irrespective of SIX2 mutation [26,27].
Previously, we used a ubiquitously expressing Cre transgene to
mosaically ablate Wt1 in the genetic background of Igf2 upregulation
(U-Wt1-Igf2) [26]. These mice had an earlier onset (10 weeks) and a
higher frequency of tumor development (80%) than the C-Wt1-Igf2
tumors in the current study (onset at 25th week and an overall tumor
frequency of 50%). Although these two models carry the same genetic
mutations, the differences in tumor onset and penetration may be due
to differences in the differentiation status of the cells when the
mutations are introduced. Many human tumors are thought to arise
from intermediate mesoderm which may be the cell of origin for the
U-Wt1-Igf2 tumors, as opposed to the more differentiated cells that
were targeted by use of the Cited1-Cre transgene.
Transformation of Nephron Progenitors by β-Catenin
Stabilization Does Not Require Wt1 Ablation
WT1 ablation and CTNNB1 mutation that result in β-catenin
stabilization are highly concordant in human Wilms tumors [11,9].
All CTNNB1 mutations reported to date are somatic and those that
affect residues encoded in exon 3 that are critical for β-catenin
stability almost invariably occur in the presence of Wt1 ablation
[11,9,28]. Thus, our observation when we genotyped mouse tumors
from Six2GCE; Wt1−/fl; Ctnnb1+/ex3(fl) and CitedCre; Wt1−/fl;
Ctnnb1+/ex3(fl) mice that only one of six tumors displayed complete
Wt1 ablation was highly unexpected. Because this was observed in
both the S-Wt1-β-catS and C-Wt1-β-catS cohort tumors, Six2
haploinsufficiency is likely not a factor in this unexpected finding.
In addition, the presence or absence of Wt1 ablation did not result in
a statistically significant difference in the frequency or age at which
tumors developed. Cohorts with a Wt1−/fl genotype developed
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Wt1+/+ genotype (Figure 2). Although analysis of larger cohorts
might, in the future, identify subtle differences in tumor susceptibility
between these different genotypes, the current data demonstrate that
Wt1 ablation in addition to β-catenin stabilization is not required for
tumorigenesis of nephron progenitors.
The observation that Ctnnb1 mutation targeted to nephron
progenitors resulted in tumors in the absence of Wt1 mutations is in
interesting contrast with human tumors in which CTNNB1 mutations
are frequently associated withWT1mutations [11]. In addition, a subset
of human tumors (subset 1) proposed to arise from postinduction
nephron progenitors carries neither Ctnnb1 nor Wt1 mutations [9],
although, like the Ctnnb1-mutant mouse tumors arising from targeted
nephron progenitors, they exhibit a differentiated epithelial histology.
Whether Ctnnb1 mutation is sufficient for cell transformation in
uncommitted metanephric mesenchyme is not known. Somatic
deletion of exon 3 of Ctnnb1 using the ubiquitously expressing
inducible Cre allele resulted in embryonic lethality even when Cre
activity was induced in b5% of cells (Huff, unpublished data). This
observation is consistent with the importance of the Wnt/β-catenin
pathway and its precise regulation in many developmental processes.
Thus, the assessment of the ability of β-catenin stabilization alone to
transform uncommitted cells of the embryonic kidney awaits the use
of a Cre allele that specifically targets these cells.
Histologic and Gene Expression Differences between Tumors
Tumors from C-Wt1-β-catS and S-Wt1-β-catS cohorts were
primarily composed of epithelial cells with few stromal and negligible
blastemal components. This is consistent with observations that Wnt
pathway activation stimulates epithelialization of induced SIX2+-only
nephron progenitors [29,8]. The epithelial histology of these mouse
tumors when a committed nephron progenitor is targeted is similar to
that observed in human subset 1 tumors which are thought to arise
late in kidney development [9]. Interestingly, CTNNB1 mutations
are not present in S1 tumors [9]. These data suggest that, for the
differentiated epithelial-predominant tumors, cell ontogeny plays a
bigger role in determining tumor histology than does the genetic
alteration present.
In contrast to the histology of tumors from C-Wt1-β-catS and
S-Wt1-β-catS cohorts, stromal and blastemal cells were more frequent
in tumors from C-Wt1-Igf2 cohorts, although not to the extent
observed when a ubiquitously expressed Cre allele was employed to
ablate Wt1 in the context of Igf2 biallelic expression (Figure 1). In
general, differences in gene expression were also observed between
genotypes rather than between the Cre alleles used to target cells.
With few exceptions, no difference in gene expression was observed
between tumors from S-Wt1-β-catS and tumors from C-Wt1-β-catS
mice. In contrast, tumors from S-Wt1-β-catS and C-Wt1-β-catS mice
were significantly different from tumors from C-Wt1-Igf2 mice, and
the latter tumors were very similar to U-Wt1-Igf2 tumors with respect
to the expression of genes expressed during kidney development that
are targets of Wnt/β-catenin signaling.
Like human subset 2 and 3 tumors in which WT1 and CTNNB1
mutations are frequently observed (along with IGF2 LOH/LOI),
genes normally expressed in intermediate mesoderm and early
metanephric mesenchyme were highly expressed in both
C-Wt1-Igf2 and U-Wt1-Igf2 tumors relative to normal kidney and
to tumors from the S-Wt1-β-catS and C-Wt1-β-catS cohorts
(Figure 5). This is of particular interest because the expression ofintermediate mesoderm genes is more concordant with tumor
genotype than it is with the Cre transgene used for introducing
gene alterations. Like human S2 and S3 tumors, it has been suggested
that the U-Wt1-Igf2 tumors arise from intermediate mesoderm or
early metanephric mesenchyme, in large part due to the fetal age
(~E12) at which the alterations were induced. The observation of
tumors with a similar histology and a similar gene expression profile
following the introduction of those same alterations at a much later
stage of kidney development (~E18) is unexpected. Of note,
C-Wt1-β-catS tumors did not display a predominant histology of
blastemal cells that are most reminiscent of intermediate mesen-
chyme. These data suggest that Wt1 ablation and Igf2 biallelic
expression, but not Ctnnb1 mutation, in the CitedCre-targeted
committed nephron progenitors result in the reexpression of these
early genes and/or results in partial dedifferentiation of these cells
which secondarily results in expression of these genes. The fact that
the C-Wt1-Igf2 and U-Wt1-Igf2 tumors (but not tumors from
S-Wt1-β-catS and C-Wt1-β-catS mice) also displayed increased
expression of two genes, Wnt4 and Jag1, that characterize nephron
progenitors induced to epithelialize and that are subsequently
downregulated is consistent with the presence of epithelial elements
in the tumors, in additional to blastemal and stromal elements.
S2 and S3 tumors also showed expression of genes associated with
muscle differentiation (e.g., MYH3, TTN, ACTA1) as compared with
other tumor subsets, although heterologousmuscle elements were often
not observed histologically. Such elements were not observed in the
mouse tumors, although we did observe a statistically significant, but
variable, upregulation of Pax3, Ttn, and Acta1 in mouse tumors
compared with normal kidney (Supplementary Figure 1).
Lack of Tumor Development Following Mutational Targeting
of Stromal Progenitors
In contrast to the tumor development observed when nephron
progenitors were targeted, no tumors were observed when mutations
were targeted to renal stromal progenitors using the Foxd1GCE Cre
allele (Table 2). Although it is possible that these progenitors have a
low-level capacity to be transformed by either combination of
alterations we introduced (or by different alterations that were not
tested here), these data demonstrate that there is a statistically
significant difference in the tumorigenic potential of these two
different progenitor populations. Human tumors that, from gene
expression profiling, are thought to arise from a similar population of
undifferentiated metanephric mesenchyme display varying histolo-
gies, including a mixed triphasic histology and a stromal predominant
histology, even in tumors withWT1mutations [9]. Thus, the human
data and the mouse data presented here suggest that the
presence—and sometimes even the predominance—of stromal
elements in tumors is not necessarily due to these tumors arising
from a committed stromal progenitor. Rather, a stromal histology may
be the result of aberrant intermediate renal mesoderm whose normal
constraints on cell fate decisions are loosened, resulting in tumors with
varying populations of cell types normally observed upon
differentiation—e.g., ductal epithelium and stroma—along with
heterologous elements (muscle and cartilage). These data, however,
do not preclude the possibility that some tumors do arise from stroma.
Conclusions
In sum, these data suggest that mutation of nephron progenitors, but
not stromal progenitors, results in tumor development, at least with
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were introduced into the progenitors. Using gene expression data from
human tumors, a model for Wilms tumor ontogeny was developed
such that tumors expressing genes characteristic of intermediate
mesoderm or early metanephric mesenchyme were proposed to have
arisen from cells at these early stages of kidney development. Although
this may be the case in general, our experimental data in mice indicate
that, even at a later stage, committed nephron progenitors can give rise
to tumors. In the case of Ctnnb1 mutation, tumors arising from these
progenitors are histologically well differentiated and do not express
genes characteristic of earlier stages of kidney development. However,
tumors with a more triphasic histology and expression of these early
kidney genes are observed when Wt1 ablation and Igf2 biallelic
expression are introduced. These data suggest that this combination of
alterations can effect a reprogramming of committed nephron
progenitors. This model is supported by the observations that ablation
of Wt1 results in a block in differentiation of the metanephric
mesenchyme [10] and that, in the testes, Wt1 ablation results in the
transdifferentiation of Sertoli cells to fetal-like Leydig cells [30].
C-Wt1-Igf2 tumors were similar histologically and with respect to
gene expression to tumors rising from the nontargeted introduction of
these same alterations into fetal kidney (U-Wt1-Igf2 tumors).
Whether this is due to the ability of these alterations to reprogram
committed nephron progenitors to an early metanephric mesen-
chyme state or because the U-Wt1-Igf2 tumors arise from committed
nephron progenitors is not known. The two sets of tumors do differ
with respect to the expression of C-myc, suggesting some difference in
tumor ontogeny. It will be informative in the future to specifically
target early metanephric mesenchyme and determine the tumorige-
nicity of these cells and the histologic and gene expression
characteristics of resulting tumors.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2015.12.001.
Acknowledgements
This work was supported by CPRIT grant (RP110324), National
Cancer Institute Cancer Center Support Grant (CA16672),
National Institutes of Health grants (CA34936 and DK069599),
CPRIT research training award (RP140106, L.H.), and a Julia Jones
Matthews Cancer Research training award. The Foxd1GCE, Six2GCE, and
Cited1Cremouse lineswere generously provided byAndrewMcMahon and
Mark deCaestecker, respectively.
References
[1] Mugford JW, Sipila P, McMahon JA, and McMahon AP (2008). Osr1
expression demarcates a multi-potent population of intermediate mesoderm that
undergoes progressive restriction to an Osr1-dependent nephron progenitor
compartment within the mammalian kidney. Dev Biol 324, 88–98.
[2] Kobayashi A, Mugford JW, Krautzberger AM, NaimanN, Liao J, andMcMahon
AP (2014). Identification of a multipotent self-renewing stromal progenitor
population during mammalian kidney organogenesis. Stem Cell Reports 3,
650–662.
[3] Brunskill EW, Park JS, Chung E, Chen F, Magella B, and Potter SS (2014).
Single cell dissection of early kidney development: multilineage priming.
Development 141, 3093–3101.
[4] Boyle S, Misfeldt A, Chandler KJ, Deal KK, Southard-Smith EM, Mortlock
DP, Baldwin HS, and de Caestecker M (2008). Fate mapping using
Cited1-CreERT2 mice demonstrates that the cap mesenchyme contains
self-renewing progenitor cells and gives rise exclusively to nephronic epithelia.
Dev Biol 313, 234–245.[5] Kobayashi A, Valerius MT, Mugford JW, Carroll TJ, Self M, Oliver G, and
McMahon AP (2008). Six2 defines and regulates a multipotent self-renewing
nephron progenitor population throughout mammalian kidney development.
Cell Stem Cell 3, 169–181.
[6] Humphreys BD, Lin SL, Kobayashi A, Hudson TE, Nowlin BT, Bonventre JV,
Valerius MT, McMahon AP, and Duffield JS (2010). Fate tracing reveals the
pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol
176, 85–97.
[7] Mugford JW, Yu J, Kobayashi A, and McMahon AP (2009). High-resolution
gene expression analysis of the developing mouse kidney defines novel cellular
compartments within the nephron progenitor population. Dev Biol 333,
312–323.
[8] Brown AC, Muthukrishnan SD, Guay JA, Adams DC, Schafer DA, Fetting JL,
and Oxburgh L (2013). Role for compartmentalization in nephron progenitor
differentiation. Proc Natl Acad Sci U S A 110, 4640–4645.
[9] Gadd S, Huff V, Huang CC, Ruteshouser EC, Dome JS, Grundy PE, Breslow
N, Jennings L, Green DM, and Beckwith JB, et al (2012). Clinically relevant
subsets identified by gene expression patterns support a revised ontogenic model
of Wilms tumor: a Children's Oncology Group Study. Neoplasia 14, 742–756.
[10] Hu Q, Gao F, Tian W, Ruteshouser EC, Wang Y, Lazar A, Stewart J, Strong LC,
Behringer RR, and Huff V (2011). Wt1 ablation and Igf2 upregulation in mice
result in Wilms tumors with elevated ERK1/2 phosphorylation. J Clin Invest
121, 174–183.
[11] Maiti S, Alam R, Amos CI, and Huff V (2000). Frequent association of
beta-catenin and WT1 mutations in Wilms tumors. Cancer Res 60, 6288–6292.
[12] Boyle S, Shioda T, Perantoni AO, and de Caestecker M (2007). Cited1 and
Cited2 are differentially expressed in the developing kidney but are not required
for nephrogenesis. Dev Dyn 236, 2321–2330.
[13] Madisen L, Zwingman TA, Sunkin SM, Oh SW, Zariwala HA, Gu H, Ng LL,
Palmiter RD, Hawrylycz MJ, and Jones AR, et al (2010). A robust and
high-throughput Cre reporting and characterization system for the whole mouse
brain. Nat Neurosci 13, 133–140.
[14] Kreidberg JA, Sariola H, Loring JM,Maeda M, Pelletier J, Housman D, and Jaenisch
R (1993). WT-1 is required for early kidney development. Cell 74, 679–691.
[15] Gao F, Maiti S, Alam N, Zhang Z, Deng JM, Behringer RR, Lecureuil C,
Guillou F, and Huff V (2006). TheWilms tumor gene, Wt1, is required for Sox9
expression and maintenance of tubular architecture in the developing testis. Proc
Natl Acad Sci U S A 103, 11987–11992.
[16] Harada N, Tamai Y, Ishikawa T, Sauer B, Takaku K, Oshima M, and Taketo
MM (1999). Intestinal polyposis in mice with a dominant stable mutation of the
beta-catenin gene. EMBO J 18, 5931–5942.
[17] Leighton PA, Ingram RS, Eggenschwiler J, Efstratiadis A, and Tilghman SM
(1995). Disruption of imprinting caused by deletion of the H19 gene region in
mice. Nature 375, 34–39.
[18] Mokkapati S, Niopek K, Huang L, Cunniff KJ, Ruteshouser EC, deCaestecker
M, Finegold MJ, and Huff V (2014). beta-catenin activation in a novel liver
progenitor cell type is sufficient to cause hepatocellular carcinoma and
hepatoblastoma. Cancer Res 74, 4515–4525.
[19] Hayashi S and McMahon AP (2002). Efficient recombination in diverse tissues
by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene
activation/inactivation in the mouse. Dev Biol 244, 305–318.
[20] Clark PE, Polosukhina D, Love H, Correa H, Coffin C, Perlman EJ, de
Caestecker M, Moses HL, and Zent R (2011). beta-Catenin and K-RAS
synergize to form primitive renal epithelial tumors with features of epithelial
Wilms' tumors. Am J Pathol 179, 3045–3055.
[21] Oliver G, Wehr R, Jenkins NA, Copeland NG, Cheyette BN, Hartenstein V,
Zipursky SL, and Gruss P (1995). Homeobox genes and connective tissue
patterning. Development 121, 693–705.
[22] Dunwoodie SL, Rodriguez TA, and Beddington RS (1998). Msg1 and Mrg1,
founding members of a gene family, show distinct patterns of gene expression
during mouse embryogenesis. Mech Dev 72, 27–40.
[23] Bouchard M, Souabni A, Mandler M, Neubuser A, and Busslinger M (2002).
Nephric lineage specification by Pax2 and Pax8. Genes Dev 16, 2958–2970.
[24] Park JS, Ma W, O'Brien LL, Chung E, Guo JJ, Cheng JG, Valerius MT,
McMahon JA, Wong WH, and McMahon AP (2012). Six2 and Wnt regulate
self-renewal and commitment of nephron progenitors through shared gene
regulatory networks. Dev Cell 23, 637–651.
[25] Self M, Lagutin OV, Bowling B, Hendrix J, Cai Y, Dressler GR, and Oliver G
(2006). Six2 is required for suppression of nephrogenesis and progenitor renewal
in the developing kidney. EMBO J 25, 5214–5228.
Neoplasia Vol. 18, No. 2, 2016 Nephron Progenitor Cells Give Rise to Wilms Tumors Huang et al. 81[26] Walz AL,Ooms A,Gadd S, GerhardDS, SmithMA,Guidry Auvil JM,MeerzamanD,
ChenQR,Hsu CH, and Yan C, et al (2015). Recurrent DGCR8, DROSHA, and SIX
homeodomainmutations in favorable histologyWilms tumors.CancerCell27, 286–297.
[27] Wegert J, Ishaque N, Vardapour R, Georg C, Gu Z, Bieg M, Ziegler B,
Bausenwein S, Nourkami N, and Ludwig N, et al (2015). Mutations in the
SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex
underlie high-risk blastemal type Wilms tumors. Cancer Cell 27, 298–311.
[28] Fukuzawa R, Heathcott RW, More HE, and Reeve AE (2007). Sequential WT1
and CTNNB1mutations and alterations of beta-catenin localisation in intralobarnephrogenic rests and associated Wilms tumours: two case studies. J Clin Pathol
60, 1013–1016.
[29] Kuure S, Popsueva A, Jakobson M, Sainio K, and Sariola H (2007). Glycogen
synthase kinase-3 inactivation and stabilization of beta-catenin induce nephron
differentiation in isolatedmouse and rat kidneymesenchymes. J Am Soc Nephrol 18,
1130–1139.
[30] Zhang L, Chen M, Wen Q, Li Y, Wang Y, Wang Y, Qin Y, Cui X, Yang L, and
Huff V, et al (2015). Reprogramming of Sertoli cells to fetal-like Leydig cells by
Wt1 ablation. Proc Natl Acad Sci U S A 112, 4003–4008.
